First, a bacterial reverse mutation test (Ames test) assessed AOD9604s mutagenic potential using four histidine-dependent auxotrophic mutants of Salmonella typhimurium (TA1535, TA1537, TA98, TA100) and one tryptophan-dependent auxotrophic mutant of Escherichia coli (WP2 uvrA), using both plate incorporation and pre-incubation methods at doses of 0, 1.6, 8, 40, 200, 1,000, and 2,000 g AOD9604/plate
Central Nervous System Research Studies in murine models of traumatic brain injury propose that BPC-157 may attenuate some of the consequences of injury, including hemorrhage severity, edema, and survival rates in early post-injury periods
Regulatory Notice BPC-157 may not be FDA-approved for certain wellness, recovery, or performance-related uses discussed on this website
peptides are no exception